How do you reconstitute PT-141?

PT-141 (bremelanotide) is a water-soluble cyclic heptapeptide, so reconstitution is straightforward as a laboratory-handling procedure. Bacteriostatic water — sterile water with about 0.9% benzyl alcohol as a preservative — is introduced slowly down the inside wall of the vial rather than aimed at the powder cake, then the vial is swirled gently to dissolve. It should never be shaken, because shaking shears the peptide and can denature it. A common 10 mg vial reconstituted with 2 mL of bacteriostatic water gives a 5 mg/mL solution. This is research handling information for non-clinical work, not a use instruction.

Is PT-141 administered subcutaneously?

In the clinical-development record, the route carried onto the approved prescription product is subcutaneous — that is the route the pivotal phase-3 programme used. Earlier development also examined an intranasal route, but a phase-1 study found that a 20 mg intranasal dose delivered only roughly 1 to 2 times the systemic exposure of the much smaller subcutaneous dose, and the intranasal formulation did not advance commercially. This describes how two administration routes deliver the molecule in the research and regulatory record; it is a route comparison, not a usage recommendation. The research-grade compound is supplied for non-clinical investigation only and has no validated research dose.

What dose of PT-141 was used in the trials?

The pivotal programme — two phase-3 randomised controlled trials in premenopausal women (PMID 31599840) — administered bremelanotide at 1.75 mg subcutaneously on an as-needed basis. An earlier dose-finding randomised controlled trial in premenopausal women (PMID 27181790) examined a subcutaneous range of 0.75 to 1.75 mg. These are facts about what the trials administered and what a regulator reviewed for the FDA-approved prescription medicine. They are not a protocol for the research-grade material, which has no validated research dose, and nothing here is a dosing recommendation or medical advice.

How many mg are in a PT-141 vial?

PT-141 (bremelanotide) is most commonly supplied as a lyophilised powder at 10 mg per vial, though other sizes exist. The vial label should state the mass in milligrams of peptide free-base and note the salt form, which is usually acetate or trifluoroacetate. A 10 mg vial reconstituted with 2 mL of bacteriostatic water gives a 5 mg/mL solution, so on a U-100 syringe 10 units equals 0.1 mL equals 0.5 mg. Those are laboratory arithmetic figures for non-clinical handling, not a dosing instruction. The research-grade material has no validated research dose and is research-use-only.

Research · PT-141 cluster

PT-141 dosing research protocols — the cyclic peptide, reconstitution, handling

Creator: Wellness Labs Editorial
Published: 2026-06-12
Keywords: PT-141 dosing, PT-141 dosing, bremelanotide dose, how to reconstitute PT-141, PT-141 reconstitution, PT-141 subcutaneous, PT-141 storage, PT-141 protocol

Wellness Labs Editorial·12 June 2026·8 min read

Medically reviewed by

Wellness Labs Research Team · Research and Editorial

Last reviewed 1 June 2026

Almost every research peptide in this catalogue shares one awkward fact about dosing: there is no validated human dose, because the molecule has never been through the kind of regulatory dose-finding programme that would establish one. PT-141 — molecular name bremelanotide — is the exception. Its active ingredient is also the active in an FDA-approved prescription product, which means a regulator-reviewed human dose figure genuinely exists in the public record. That makes the dosing question here different from every other spoke we publish — and it makes the discipline more important, not less. The reviewed figure is a fact about the approved medicine. It is not a protocol for the research-grade material, which remains research-use-only.

TL;DR

PT-141 (bremelanotide) is the one molecule in this catalogue whose active ingredient is also in an FDA-approved prescription product — approved in 2019 for a specific indication — so unlike the other research peptides here, a regulator-reviewed human dose figure exists. The pivotal phase-3 programme in premenopausal women administered 1.75 mg subcutaneously on an as-needed basis [1]; an earlier dose-finding study examined subcutaneous 0.75–1.75 mg [2]; the approved route is subcutaneous, while earlier development used intranasal (a phase-1 study found intranasal 20 mg gave roughly 1–2× the subcutaneous exposure) which did not advance commercially [3]. Read all of that as a property of the approved medicine, not a usage recommendation. PT-141 is a cyclic heptapeptide of roughly 1,025 Da, water-soluble; a 10 mg vial in 2 mL gives 5 mg/mL, so on a U-100 syringe 10 units = 0.1 mL = 0.5 mg — laboratory handling math, not a use instruction. Store lyophilised at -20°C, dark; reconstituted, 2–8°C for about 28 days. For the research-grade material there is no validated research dose. Research use only — not a substitute for the approved prescription medicine. See the PT-141 parent synopsis.

The unusual dosing situation

Start with what makes this molecule different. When you read our other dosing spokes — Epitalon, the growth-hormone-secretagogue family, the bioregulators — they all open the same way: there is no validated human dose, because none of those molecules is an approved medicine and none has been through a registration-grade dose-finding programme. The figures that circulate for them are extrapolations from a thin research record, not regulator-reviewed numbers.

Bremelanotide breaks that pattern. The active ingredient in PT-141 is also the active in a prescription product that received FDA approval in 2019 for a specific indication. Going through that approval meant going through the full clinical-development machinery — including the phase-3 trials that fix a dose and route on the regulator-reviewed label. So for this molecule, and almost no other in the catalogue, a reviewed human dose figure genuinely exists: a subcutaneous, on-demand (as-needed) dose, examined in controlled trials and carried onto an approved label.

A regulator-reviewed human dose figure for bremelanotide exists. That is a fact about the approved prescription medicine — not a protocol for the research-grade material, which has no validated research dose and is research-use-only.

That distinction is the entire discipline of this article, so it is worth stating as plainly as possible. The existence of a reviewed dose does not make the research-grade compound a medicine, and it is nota usage recommendation for it. The approved product is a registered prescription medicine with its own manufacturer, quality-control regime, formulation, and clinical-use protocols; the research-grade peptide is a lyophilised powder supplied for non-clinical investigation, with no claim of clinical equivalence. The number below tells you what a regulator reviewed for the approved medicine. It does not tell anyone what to do with the research-grade material — and nothing here is medical advice or a dosing instruction for any person.

The figures the trials and approval used

Because the figures here come from a real regulatory record rather than forum lore, it is worth being precise about which study contributed which number — and describing each study purely by its design, never by what it measured.

The phase-3 programme. Two phase-3 randomised controlled trials in premenopausal women, reported together by Kingsberg, Clayton and colleagues, administered bremelanotide at 1.75 mg subcutaneously on an as-needed basis [1]. This is the dose and route that the pivotal programme administered and that carried onto the approved label — described here as what the programme gave, by its design (phase-3, premenopausal women, subcutaneous, on-demand), not by its endpoints.
The dose-finding study. An earlier dose-finding randomised controlled trial in premenopausal women examined a range of subcutaneous doses spanning 0.75–1.75 mg [2]. Dose-finding studies exist precisely to bracket a range before a pivotal dose is fixed; the 1.75 mg figure that the phase-3 programme settled on sits at the top of the range this study examined.

Read those figures as “what the programme administered”, full stop. They describe a subcutaneous, on-demand dose that a regulator reviewed for an approved prescription medicine. They are not a regimen for the research-grade compound, and presenting them as one would both misrepresent the literature and ignore the fact that the research-grade material is supplied for non-clinical investigation only.

Route note — subcutaneous vs intranasal

The route is worth a paragraph of its own, because the development history shows two of them and only one survived to approval. The approved route is subcutaneous— that is the route the phase-3 programme used and the one fixed on the approved label. But bremelanotide’s earlier development explored an intranasal route, and the pharmacokinetic comparison is genuinely informative for anyone studying administration.

A phase-1 safety and pharmacokinetic study reported that an intranasal dose of 20 mg delivered roughly 1–2× the systemic exposure of the subcutaneous route, while characterising the safety and tolerability profile of the two routes [3]. The headline numbers tell the story of why subcutaneous won out: it takes a far larger intranasal dose (20 mg) to reach exposure in the same ballpark as a low-milligram subcutaneous dose, because intranasal absorption is comparatively inefficient. The intranasal formulation did not advance to commercial development. This is administration-route research — a comparison of how two routes deliver the molecule — not a use instruction for either.

Reconstitution & the syringe math

As a molecule to handle, PT-141 is a cyclic heptapeptide — seven residues, molecular weight approximately 1,025 Da, supplied as the acetate or trifluoroacetate (TFA) salt — and it is water-soluble, so reconstitution itself is straightforward. The cyclic structure matters for purity verification (covered below) but does not complicate dissolving the powder. The general diluent and documentation framework lives in our how to reconstitute research peptidesguide; the arithmetic below shows how a chosen mass in milligrams maps onto syringe units, as laboratory handling math — not a use instruction.

Mechanically, the procedure is the same as for any lyophilised peptide: introduce bacteriostatic water— sterile water with roughly 0.9% benzyl alcohol as a preservative — slowly down the inside wall of the vial rather than aiming the stream at the powder cake, then swirl gently to dissolve. Never shake: shaking shears the peptide and can denature it. The worked example below assumes the common 10 mg vial.

Reconstitution math (research reference)

A vial labelled PT-141 10 mg reconstituted with 2 mL of bacteriostatic water yields a concentration of 5 mg/mL; with 1 mL it yields 10 mg/mL; with 5 mL it yields 2 mg/mL.
On a U-100 insulin syringe (100 units = 1 mL), 0.1 mL = 10 units. At 5 mg/mL (the 10 mg vial in 2 mL), 10 units = 0.1 mL = 0.5 mg; 4 units (0.04 mL) draws 0.2 mg; 20 units (0.2 mL) draws 1 mg.
Diluent: standard bacteriostatic water. Introduce it slowly down the vial wall, not onto the powder cake, then swirl — do not shake.
The free reconstitution calculator handles any vial-size / diluent-volume / draw-volume combination.
These figures are laboratory handling arithmetic. They are not a human dosing recommendation — the research-grade material has no validated research dose, and the regulator-reviewed dose figure cited elsewhere in this article is a property of the approved prescription medicine, not guidance for this compound. For research use only — not for human consumption.

Storage & handling

As a lyophilised powder PT-141 is most stable at -20°C, protected from light; once reconstituted, the solution is generally kept refrigerated at 2–8°C and is typically rated for about 28 daysin that state. Bacteriostatic water’s benzyl alcohol preservative is what allows a reconstituted multi-use vial to remain usable across that window rather than being a single-use preparation.

The handling subtlety specific to this molecule is a quality-control one rooted in its chemistry. PT-141 is a cyclic peptide, which makes it more synthesis-intensive than a linear peptide of equivalent length — the ring has to be closed correctly, and getting that wrong produces impurities that a casual buyer never sees. That extra synthetic difficulty translates directly into meaningful vendor-to-vendor purity variance, which makes third-party verification more important, not less. A research-grade material should arrive with an RP-HPLC purity assay of ≥98% peak area and mass-spectrometry confirmation of the parent ion at roughly 1,026 Da [M+H]⁺, consistent with the ~1,025 Da heptapeptide. Without that documentation, the “dose” implied by the label is only as trustworthy as the mass — and the identity — actually in the vial.

Cycles and “protocols” — what applies and what does not

For most molecules in this catalogue the “cycle” question is answered by pointing out that the circulating multi-week schedules are convention, not evidence. PT-141 is again a special case, and the honesty cuts the other way: the on-demand (as-needed) schedule that exists is not a forum convention at all — it is a property of the approved prescription medicine, fixed through the phase-3 programme and carried onto the regulator-reviewed label [1]. That makes it a real, reviewed schedule. It also makes it firmly off-limits as guidance for the research-grade material.

The distinction to hold onto is between what the record describes for the approved medicine and what would be validated for thiscompound. The approved product’s as-needed schedule is exactly that — a schedule for the approved product, dispensed under prescription, with its own formulation and clinical-use protocols. For the research-grade material there is no validated research protocol: no cycle length, no frequency, no dose that has been established for non-clinical use. So the answer to “what is the PT-141 protocol?” is twofold and must stay twofold: there is a regulator-reviewed on-demand schedule that belongs to the approved prescription medicine, and there is no validated protocol for the research-grade compound. Conflating the two is precisely the error this article exists to prevent.

The on-demand schedule is real — but it belongs to the approved prescription medicine. For the research-grade material there is no validated research protocol, and the approved schedule is not guidance for it.

What an honest research-grade PT-141 label / COA should show

Active ingredient stated as “bremelanotide” or “PT-141” — both are correct chemical names for the same molecule.
Mass per vial in mg of peptide free-base, with the salt form noted (acetate or TFA is standard).
Third-party RP-HPLC purity assay, ≥98% peak area, with the batch number on the COA. Mass-spectrometry confirmation of the parent ion at roughly 1,026 Da [M+H]⁺, consistent with the ~1,025 Da cyclic heptapeptide.
Storage at -20°C protected from light; reconstituted shelf-life at 2–8°C (about 28 days) stated on the documentation.
Explicit “for research use only — not for human consumption” statement. The compound is not a substitute for the FDA-approved prescription medicine that contains the same active ingredient, and the label carries no validated research dose.

For what PT-141 is and where its research record stands, start with the PT-141 (bremelanotide) parent synopsis. For the molecular biology, see PT-141 mechanism research; to place it against its structural relative, see PT-141 vs Melanotan II. For general diluent and documentation handling, see how to reconstitute research peptides, and run any vial-size / concentration / draw-volume combination through the free reconstitution calculator. Supply: PT-141 10 mg research-consultation page.

Frequently asked questions

How do you reconstitute PT-141?: PT-141 (bremelanotide) is a water-soluble cyclic heptapeptide, so reconstitution is straightforward as a laboratory-handling procedure. Bacteriostatic water — sterile water with about 0.9% benzyl alcohol as a preservative — is introduced slowly down the inside wall of the vial rather than aimed at the powder cake, then the vial is swirled gently to dissolve. It should never be shaken, because shaking shears the peptide and can denature it. A common 10 mg vial reconstituted with 2 mL of bacteriostatic water gives a 5 mg/mL solution. This is research handling information for non-clinical work, not a use instruction.
Is PT-141 administered subcutaneously?: In the clinical-development record, the route carried onto the approved prescription product is subcutaneous — that is the route the pivotal phase-3 programme used. Earlier development also examined an intranasal route, but a phase-1 study found that a 20 mg intranasal dose delivered only roughly 1 to 2 times the systemic exposure of the much smaller subcutaneous dose, and the intranasal formulation did not advance commercially. This describes how two administration routes deliver the molecule in the research and regulatory record; it is a route comparison, not a usage recommendation. The research-grade compound is supplied for non-clinical investigation only and has no validated research dose.
What dose of PT-141 was used in the trials?: The pivotal programme — two phase-3 randomised controlled trials in premenopausal women (PMID 31599840) — administered bremelanotide at 1.75 mg subcutaneously on an as-needed basis. An earlier dose-finding randomised controlled trial in premenopausal women (PMID 27181790) examined a subcutaneous range of 0.75 to 1.75 mg. These are facts about what the trials administered and what a regulator reviewed for the FDA-approved prescription medicine. They are not a protocol for the research-grade material, which has no validated research dose, and nothing here is a dosing recommendation or medical advice.
How should PT-141 be stored?: As a lyophilised powder, PT-141 (bremelanotide) is most stable stored at -20°C, protected from light. Once reconstituted in bacteriostatic water, the solution is generally kept refrigerated at 2-8°C and is typically rated for about 28 days in that state; the benzyl alcohol preservative is what allows a reconstituted multi-use vial to remain usable across that window. Because PT-141 is a cyclic peptide that is more synthesis-intensive than a linear peptide, purity varies between vendors, so a certificate of analysis showing RP-HPLC purity of at least 98% and mass-spectrometry confirmation is worth checking. This is research handling information, not medical advice.
How many mg are in a PT-141 vial?: PT-141 (bremelanotide) is most commonly supplied as a lyophilised powder at 10 mg per vial, though other sizes exist. The vial label should state the mass in milligrams of peptide free-base and note the salt form, which is usually acetate or trifluoroacetate. A 10 mg vial reconstituted with 2 mL of bacteriostatic water gives a 5 mg/mL solution, so on a U-100 syringe 10 units equals 0.1 mL equals 0.5 mg. Those are laboratory arithmetic figures for non-clinical handling, not a dosing instruction. The research-grade material has no validated research dose and is research-use-only.